Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js
Vertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue Growth
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 billion,
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.88 billion,
Vertex Pharmaceuticals reports Q4 EPS $3.98, consensus $4.02
Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another
Vertex Pharmaceuticals Posts Higher 4Q Revenue
For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early contributions from Journavx, a treatment for adults with moderate-to-severe acute pain.
Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% last quarter,
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Top Vertex exec to retire after more than 12 years with company
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
Vertex Q4 revenue beats Street, guidance in line with consensus
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B
Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B Sees FY25 R&D, AIPR&D and SG&A expenses of $4.9B-$5.0B.
2 Biotech Stocks to Buy Hand Over Fist in February
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...